Timothy P. Heffernan

18.2k total citations
38 papers, 1.3k citations indexed

About

Timothy P. Heffernan is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Timothy P. Heffernan has authored 38 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 17 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Timothy P. Heffernan's work include Cancer-related Molecular Pathways (10 papers), DNA Repair Mechanisms (9 papers) and Melanoma and MAPK Pathways (5 papers). Timothy P. Heffernan is often cited by papers focused on Cancer-related Molecular Pathways (10 papers), DNA Repair Mechanisms (9 papers) and Melanoma and MAPK Pathways (5 papers). Timothy P. Heffernan collaborates with scholars based in United States, Austria and United Kingdom. Timothy P. Heffernan's co-authors include William K. Kaufmann, Marila Cordeiro‐Stone, Dennis A. Simpson, Alexandra N. Heinloth, Richard S. Paules, Christopher A. Bristow, P. Andrew Futreal, Scott Kopetz, Jeffrey J. Kovacs and Joseph R. Marszalek and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Timothy P. Heffernan

34 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Timothy P. Heffernan United States 18 837 476 378 210 176 38 1.3k
Ion Cristóbal Spain 22 1.1k 1.3× 430 0.9× 489 1.3× 194 0.9× 92 0.5× 58 1.5k
Daniel Ratschiller Switzerland 15 721 0.9× 488 1.0× 476 1.3× 219 1.0× 185 1.1× 18 1.3k
Steven Pirie‐Shepherd United States 19 815 1.0× 356 0.7× 398 1.1× 138 0.7× 99 0.6× 36 1.4k
Lesley Mathews United States 15 862 1.0× 604 1.3× 374 1.0× 127 0.6× 82 0.5× 21 1.4k
Maroulio Talieri Greece 27 1.1k 1.3× 683 1.4× 528 1.4× 197 0.9× 494 2.8× 57 1.9k
Zainab Jagani United States 14 1.5k 1.8× 544 1.1× 196 0.5× 161 0.8× 136 0.8× 15 1.8k
Sauveur-Michel Maira Switzerland 8 952 1.1× 343 0.7× 310 0.8× 76 0.4× 194 1.1× 8 1.2k
Jingda Xu China 17 771 0.9× 643 1.4× 242 0.6× 141 0.7× 100 0.6× 24 1.4k
Meaghan Wall Australia 23 983 1.2× 330 0.7× 166 0.4× 266 1.3× 276 1.6× 57 1.6k
Chun-Ju Chang United States 9 980 1.2× 529 1.1× 445 1.2× 77 0.4× 63 0.4× 10 1.3k

Countries citing papers authored by Timothy P. Heffernan

Since Specialization
Citations

This map shows the geographic impact of Timothy P. Heffernan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy P. Heffernan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy P. Heffernan more than expected).

Fields of papers citing papers by Timothy P. Heffernan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy P. Heffernan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy P. Heffernan. The network helps show where Timothy P. Heffernan may publish in the future.

Co-authorship network of co-authors of Timothy P. Heffernan

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy P. Heffernan. A scholar is included among the top collaborators of Timothy P. Heffernan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy P. Heffernan. Timothy P. Heffernan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Benjamin H., Geraldine L. C. Paulus, Michael F. Princiotta, et al.. (2024). CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo. Blood. 144(Supplement 1). 208–208.
2.
Shi, Chunhua, Guojun Yang, Qing Shi, et al.. (2023). Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia. 37(10). 2006–2016. 6 indexed citations
3.
Osman, Abdullah A., Emre Arslan, Chieko Michikawa, et al.. (2023). Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 29(7). 1344–1359. 32 indexed citations
4.
Lightfoot, Yaíma L., Jeffrey J. Molldrem, Timothy P. Heffernan, et al.. (2023). Anti‐MS4A4A Antibody Modulates Myeloid Cell Biology and TREM2 Signaling. Alzheimer s & Dementia. 19(S21).
5.
6.
Liang, Yan, Bo Tu, Jun Yao, et al.. (2021). Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Research. 81(15). 4054–4065. 30 indexed citations
7.
Shariati, Maryam, Kurt W. Evans, Xiaofeng Zheng, et al.. (2021). Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene. 40(26). 4425–4439. 17 indexed citations
8.
Han, Jing, Mikhila Mahendra, Joseph R. Daniele, et al.. (2021). Abstract 985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models. Cancer Research. 81(13_Supplement). 985–985. 1 indexed citations
9.
Hofmann, Marco H., Hengyu Lu, Daniel Gerlach, et al.. (2021). Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.. Cancer Research. 81(13_Supplement). CT210–CT210. 13 indexed citations
10.
Yap, Timothy A., Ecaterina E. Dumbrava, Jordi Rodón, et al.. (2021). First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 3001–3001. 11 indexed citations
11.
Redwood, Abena B., Xiaomei Zhang, Sahil Seth, et al.. (2021). The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors. npj Breast Cancer. 7(1). 152–152. 9 indexed citations
12.
Wu, Ji Yuan, Garth Powis, Feng Tian, et al.. (2020). Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. UNC Libraries. 5 indexed citations
13.
Powell, Emily, Jiansu Shao, Christopher A. Bristow, et al.. (2018). A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. npj Breast Cancer. 4(1). 9–9. 39 indexed citations
14.
Lee, Michael S., Timothy L. Helms, Ningping Feng, et al.. (2016). Efficacy of the combination of MEK and CDK4/6 inhibitorsin vitroandin vivoin KRAS mutant colorectal cancer models. Oncotarget. 7(26). 39595–39608. 99 indexed citations
15.
Kawasumi, Masaoki, Bianca D. Lemos, James E. Bradner, et al.. (2011). Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. Proceedings of the National Academy of Sciences. 108(33). 13716–13721. 47 indexed citations
16.
Wiedemeyer, Ruprecht, Cameron Brennan, Timothy P. Heffernan, et al.. (2008). Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. Cancer Cell. 13(4). 355–364. 93 indexed citations
17.
Chastain, Paul D., Timothy P. Heffernan, Kathleen R. Nevis, et al.. (2006). Checkpoint Regulation of Replication Dynamics in UV-Irradiated Human Cells. Cell Cycle. 5(18). 2160–2167. 47 indexed citations
18.
Simpson, Dennis A., Elizabeth Livanos, Timothy P. Heffernan, & William K. Kaufmann. (2005). Telomerase expression is sufficient for chromosomal integrity in cells lacking p53 dependent G1 checkpoint function.. Journal of Carcinogenesis. 4(1). 18–18. 16 indexed citations
19.
Nikolaishvili‐Feinberg, Nana, Miriam F. Bryant, Douglas D. Luche, et al.. (2005). Overproduction of DNA polymerase eta does not raise the spontaneous mutation rate in diploid human fibroblasts. DNA repair. 4(6). 714–724. 24 indexed citations
20.
Rossi, Gianluca Del, MaryBeth Horodyski, Timothy P. Heffernan, et al.. (2004). Spine-Board Transfer Techniques and the Unstable Cervical Spine. Spine. 29(7). E134–E138. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ion Cristóbal Breakdown of academic impact, for papers by Daniel Ratschiller Breakdown of academic impact, for papers by Steven Pirie‐Shepherd Breakdown of academic impact, for papers by Lesley Mathews Breakdown of academic impact, for papers by Maroulio Talieri Breakdown of academic impact, for papers by Zainab Jagani Breakdown of academic impact, for papers by Sauveur-Michel Maira Breakdown of academic impact, for papers by Jingda Xu Breakdown of academic impact, for papers by Meaghan Wall Breakdown of academic impact, for papers by Chun-Ju Chang
Rankless by CCL
2026